ACC @ GW-ICC Joint Forum – Great Wall International Congress of Cardiology (GW-ICC) 2017 – Non-Statin Therapy- What is the Evidence and When Do We Use Them?

It has become a tradition for world renowned cardiology associations to send delegations to GW-ICC congresses.

Professor Jeroen J. Bax, President, European Society of Cardiology (ESC), Professor John Warner, President, American Heart Association (AHA), and Professor Mary N. Walsh, President, American College of Cardiology (ACC), led delegations attending the 28^th GW-ICC, to present latest international guidance, cutting-edge diagnosis and information on treatment with emerging technologies.

Cooperation with these international societies is not limited to their attendance at GW-ICC; GW-ICC also holds reciprocal academic sessions at the annual meetings of these eminent societies, for example GW-ICC @ ACC, GW-ICC @ AHA, and GW @ ESC, to introduce important Chinese academic research.

At the 28^th GW-ICC in 2017, the ACC @ GW-ICC Joint Forum, which was held over three sessions, focused on population health, guidelines and real-world evidence; cardiovascular disease prevention: hypertension, smoking cessation and blood lipid management and systems of STEMI care.

A video of one of these 2017 sessions is now available to view on the GW-ICC YouTube channel:

Non-Statin Therapy- What is the Evidence and When Do We Use Them?

Presenter: Christie M. Ballantyne, Center for Cardiovascular Disease Prevention, Houston Methodist DeBakey Heart & Vascular Center, Baylor College of Medicine, Houston, TX, USA.

Dr Ballantyne discusses how:

• Evidence from clinical trials have conclusively shown the benefit of aggressive lowering of LDL-C in high risk individuals and all guidelines recommend initial therapy with statins.
• Asian patients must be included in clinical trials for lipid therapy as both risks and benefits have been shown to be different than western populations (i.e. statins and niacin)
• Nonstatin therapies (ezetimibe, PSCK9 inhibitors and anacetrabib) have now been shown to reduce CVD events when added to statin therapies consistent with the amount of LDL-C reduction and with safety data in Asian patients.

Further information on the 29^th GW-ICC, to be held October 11^th -14^th, 2018, in Beijing, China, is available on the congress website:

http://www.gw-icc2017.org/en/1/index.jsp

Cardiovascular Innovations and Applications (CVIA) is the official journal of the Great Wall International Cardiology Conference (GW-ICC). CVIA supports GW-ICC in its aims of leading the development of cardiovascular medicine in China, by introducing and promoting new concepts and technologies and strengthening and promoting cooperation amongst Chinese and international cardiology experts. CVIA is available on the IngentaConnect platform http://www.ingentaconnect.com/content/cscript/cvia and at https://dhn.zgc.mybluehostin.me/cvia/. Submissions may be made using Scholar One manuscripts at https:/mc04.manuscriptcentral.com/cvia-journal. There are no author submission or article processing fees.

Twitter: @CVIA_Journal

Facebook: https://www.facebook.com/cvia.journal/

Conference website: http://www.gw-icc2017.org/en/1/index.jsp